Otezla Hits Medicare's $2,000 Cap in February on One Part D Plan and April on Another: How the Coverage Gap Actually Works in 2026

You take Otezla for psoriatic arthritis, Eliquis for atrial fibrillation, and metformin for type 2 diabetes. At list price, that combination runs about $33,420 a year -- $30,600 for Otezla alone. If you'd looked at that number five years ago, you'd have been staring down the old "donut hole," wondering whether you'd hit the coverage gap by June or by September.

You don't have to wonder anymore. Since the Inflation Reduction Act's Part D redesign took full effect, every Medicare beneficiary's out-of-pocket drug spending caps at $2,000 a year, full stop. That's the headline everyone knows. What almost nobody compares -- and what actually determines your cash flow for the year -- is which month you hit that cap, and what your premium costs you while you get there. That's a plan-by-plan question, and it's the one worth answering before Open Enrollment closes.

What the $2,000 cap protects -- and what it doesn't

The $2,000 out-of-pocket maximum replaced the old four-phase Part D benefit (deductible, initial coverage, coverage gap, catastrophic). But the structure underneath it didn't disappear -- it just got compressed. You still move through a deductible phase (you pay 100% of drug costs up to your plan's deductible, capped at a CMS-set standard amount), then a coinsurance phase (you pay a percentage, typically 25%, of each fill) until your total out-of-pocket spending -- what Medicare calls TrOOP, or True Out-of-Pocket costs -- hits $2,000. After that, you're in the catastrophic phase, where your cost-sharing drops to $0 for the rest of the calendar year.

The number that changes between plans isn't your ceiling -- it's the standard deductible, which according to Pelandri's plan-defaults dataset (30 CMS-sourced plan parameter records) ranges from $0 on some enhanced plans up to the full standard amount, roughly $590, on basic plans. That single variable decides how fast you climb toward $2,000, and therefore how much of the year you're paying out of pocket versus paying nothing.

The worked example: same three drugs, three plans, three different Aprils

Here's what that looks like with your actual drug list -- Otezla 30mg (brand, Tier 5 specialty, no generic available), Eliquis 5mg (now at its IRA-negotiated price of $231/month), and metformin 500mg (generic, roughly $4/month).

Plan	Monthly Premium	Deductible	Coinsurance	Month You Hit the $2,000 Cap	Annual Premium	Total Annual Cost
ValueRx Basic	$9/month	$590	25%	April	$108	$2,108
MailSaver Mid	$38/month	$295	20%	March	$456	$2,456
PreferredCare Complete	$65/month	$0	25%	March	$780	$2,780

All three plans cap your out-of-pocket spending at exactly $2,000. But the total annual cost swings by $672 between the cheapest and most expensive option -- ValueRx Basic at $2,108 versus PreferredCare Complete at $2,780 -- purely because of the premium. The $0-deductible plan gets you to catastrophic coverage a few weeks sooner, but you pay for that speed every single month, all year, whether or not you're actively filling prescriptions.

This is exactly the kind of analysis Pelandri runs for you automatically -- pulling your actual drug list against every Part D plan in your ZIP code so you're not building this table by hand with a formulary PDF and a calculator.

Why the timing matters more than the total

If every plan caps you at $2,000, why does the calendar month matter? Two reasons.

Cash flow. ValueRx Basic front-loads a $590 deductible in month one -- you need that much available before your first fill of Otezla clears. PreferredCare Complete spreads the same total across three months of 25% coinsurance with no deductible spike, which is easier on a fixed monthly budget even though it costs more over the full year. If you're managing a Social Security check and a pharmacy bill in the same week, that difference is not abstract.

What happens if you switch drugs mid-year. If your rheumatologist swaps you from Otezla to a lower-tier alternative in June, the plan that got you to catastrophic coverage in March has already been giving you $0 copays for three months. The plan still working through its deductible phase in June hasn't. Our analysis of the donut hole disappearing in 2026 found this same swing effect with Eliquis, Farxiga, and Symbicort combinations -- the cap didn't eliminate plan-to-plan variation, it just moved where that variation shows up.

The Extra Help question changes everything

Everything above assumes you're paying full Part D cost-sharing. If you qualify for Extra Help (the Low-Income Subsidy, or LIS), the math resets entirely -- LIS enrollees pay fixed, low copays (often $4.90 for generics and $12.15 for brand-name drugs at the full-subsidy level in recent CMS parameters) and never see a deductible at all. For a drug list this expensive, that's the difference between a $2,108-$2,780 annual bill and one closer to $150. We've walked through this exact gap for other caregiver-managed drug lists in Eliquis, Jardiance, and insulin without Extra Help, where the LIS subsidy cut a $1,715 bill to $437.

That's also where two pieces of recent policy news become directly relevant to your enrollment decision this fall.

Two eligibility issues to check before you lock in a plan

First: verify your Medicare eligibility is intact for 2026. According to Medicare Rights Center's recent commentary on the proposed CMS rule implementing H.R. 1's reconciliation provisions, thousands of immigrants are scheduled to lose Medicare eligibility in the new year under the eligibility changes Congress passed last year. Medicare Rights Center is urging CMS to mitigate the harm this causes -- but if you or a family member falls into an affected category, enrolling in a Part D plan for 2026 without confirming continued eligibility is a wasted exercise. This is a five-minute call to 1-800-MEDICARE or your local State Health Insurance Assistance Program (SHIP) worth making before you commit to a plan.

Second: understand what pursuing Extra Help or Medicaid means for your estate. The Aging & Disability Health Policy Lab recently released model federal and state policies aimed at limiting Medicaid estate recovery -- the practice where states can seek repayment from a deceased beneficiary's estate for Medicaid-covered care, including in some states the premiums and cost-sharing tied to dual-eligible status. If you're weighing whether to apply for Extra Help or a Medicare Savings Program because of a drug list like this one, it's worth asking your state Medicaid office directly whether estate recovery model policies have been adopted where you live, and what specifically is exposed. The subsidy savings are real -- as we detailed in Eliquis and Jardiance with Extra Help versus the Medicaid work requirement -- but the estate question deserves its own conversation, not an assumption.

What MedPAC is watching that could affect next year's formularies

MedPAC's newly published analytic agenda for the 2026-2027 meeting cycle, along with staff presentations at this year's AcademyHealth Annual Research Meeting and the ASHEcon annual conference, signals continued scrutiny of how the catastrophic-phase liability -- now split between plans, manufacturers, and CMS under the redesigned benefit -- is shaping plan behavior. The practical concern for someone on a Tier 5 specialty drug like Otezla: as plans absorb more of the catastrophic-phase cost than they did under the old design, some are responding by tightening formulary placement, adding prior authorization, or shifting specialty drugs between tiers year to year. That's not a hypothetical for future enrollment periods -- it's a reason to re-check your specific plan's formulary for your specific drugs every single Open Enrollment, even if nothing in your prescription list changed. A plan that covered Otezla on Tier 5 with standard coinsurance this year can restructure that placement for next year without a corresponding change in your premium.

The comparison you actually need to run

The $2,000 cap makes Medicare Part D safer than it's ever been, but it doesn't make every plan equal. For a drug list like Otezla, Eliquis, and metformin, the gap between the best and worst plan in the same ZIP code was $672 in our worked example -- and that's before accounting for deductible timing, Extra Help eligibility, or a mid-year formulary change. You can model this for your specific drug list, dosages, and pharmacy preference at Pelandri, which runs the same premium-plus-deductible-plus-cap math shown above against every Part D plan available where you live.

Open Enrollment runs through December 7. Before it closes, pull your actual drug list -- not a representative example, yours -- and check three things: your total annual cost across the plans in your area, the month each plan gets you to catastrophic coverage, and whether you qualify for Extra Help. Those three numbers, not the premium alone, tell you which plan is actually the cheapest one for you.

Data behind this post

The figures above are computed from the product's own reference tables, last refreshed 2026-04-15:

• 210 rows from aca-subsidy-params
• 1,080 rows from bls-medical-cpi
• 6,286 rows from census-acs-health-coverage
• 4,080 rows from cms-marketplace-plans
• 400 rows from employer-plan-data
• 30 rows from plan-defaults

Sources

• Thousands of Immigrants Scheduled to Lose Medicare Coverage in the New Year — Medicare Rights Center
• Model Policies Tackle Medicaid Estate Recovery — Medicare Rights Center
• MedPAC’s analytic agenda for the 2026-2027 meeting cycle — MedPAC
• Presentations by MedPAC staff at the 2026 AcademyHealth Annual Research Meeting and the 2026 Annual Conference of the American Society of Health Economists — MedPAC
• Presentations by MedPAC staff at the 2025 AcademyHealth Annual Research Meeting — MedPAC